NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Senti Biosciences Holdings, Inc. (SNTI) Stock Analysis

Senti Biosciences Holdings, Inc. (SNTI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SNTI

$0.33

−$0.01 (−2.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNTI with… →

SNTI Key Statistics

As of Sep 4, 2026
Trading
Open
$0.35
Previous Close
$0.34
Day's Range
0.33–0.36
52-Week Range
0.33–2.88
Volume
133.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.12
Valuation
Market Cap
$10.36M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
188.34
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.69
Financials (FY)
Revenue (FY)
$22.00K
Net Income (FY)
−$61.44M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.14M
1-Year Return
−75.87%
Dividend and dates
Avg Volume
252.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNTI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−67.98%
2025−70.37%
2024−46.82%
2023−53.19%
2022−85.70%
2021 (partial year)−1.20%

As of September 4, 2026.

SNTI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$22.00K−$61.44M−279263.6%
2024$0.00−$52.79M—
2023$1.98M−$71.06M−3592.4%
2022$3.29M−$58.21M−1771.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$22.00K—−$63.73M−$61.44M−279263.6%
2024$0.00—−$60.73M−$52.79M—
2023$1.98M—−$66.77M−$71.06M−3592.4%
2022$3.29M—−$62.08M−$58.21M−1771.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNTI Valuation vs Biotechnology Median

Median of 656 stocks
MetricSNTIBiotechnology medianvs median
P/S ratio188.3415.2612.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Senti Biosciences Holdings, Inc. (SNTI) carries a market capitalisation of $10.36M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 39 employees.

The most recent close on file for SNTI is $0.33, dated September 4, 2026. That is −$0.01 (−2.35%) against the previous close. Over the past 52 weeks the price has ranged from $0.33 to $2.88. The latest close sits 0.6% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $22.00K. The same year closed with a net loss of $61.44M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.69.

Across the 4 fiscal years on file, revenue moves from $3.29M in 2022 to $22.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 188.34 times revenue. On price-to-sales that is 12.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.12. Daily returns over the trailing 5 years annualize to a volatility of 203.37%. Over the trailing twelve months the price has returned −75.87%. Across 5 years the annualized return works out at −67.98%.

Growth & Income

The record shows no dividend for SNTI.

Across the complete calendar years on file, 2024 returned −46.82% and 2022 returned −85.70%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is −67.98%.

Peer Comparison

Senti Biosciences Holdings, Inc. (SNTI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Senti Biosciences Holdings, Inc. SNTI $10.36M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Senti Biosciences Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit website →